Accendra Health, Inc.
NYSE:ACHMedical - Distribution
+$0.12 today
- Market cap
- $54.22M
- Beta
- 1.63
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$14.11
Volume 1.41M
Average 0.83M
ACH EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Accendra Health, Inc.NYSE: ACH
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA dips below year-ago levels
Q1 FY2026 EBITDA of $55.61M fell 7.4% year over year, behind the +949.6% change in trailing-twelve-month EBITDA. Sequentially, it fell 35.8% from the prior quarter. Over 3 fiscal years it compounded at -0.3% a year.
Context
- EBITDA amounted to 13.2% of revenue in FY2025, up 12.7 pp from a year earlier.
- EBITDA increased in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 4 analysts of $322.86M (-11.5%) for the fiscal year ending Dec 2026, a slowdown from the +612.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $55.61M-35.8% QoQ
- Last fiscal yearDec 2025
- $364.68M+612.0% YoY
- LTMMar 2026
- $344.06M+949.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -7.4% | -13.7% | -6.3 pp |
| 1 year | +612.0% | -11.5% | -623.4 pp |
| 3-year CAGR | -0.3% | -5.5% | -5.1 pp |
| 5-year CAGR | -3.1% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 364.68M USD
- Year-over-year change
- +612.0%
- 4-year CAGR
- -3.2%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 364.68M | +612.0% |
| FY2024 | 2024-12-31 | 51.22M | -86.9% |
| FY2023 | 2023-12-31 | 390.57M | +6.0% |
| FY2022 | 2022-12-31 | 368.45M | -11.3% |
| FY2021 | 2021-12-31 | 415.47M | — |
EBITDA vs competitors
How ACH compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +949.6% is the highest of 11, against a peer median of +11.0%.
- EBITDA amounts to 12.7% of revenue for ACH, versus a peer median of 71.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $344.06M USD | +949.6% | -0.3% | 12.7% | |
| LTM Apr 2026 | -CA$6.09M CAD | -121.9% | — | 0.9% | |
| LTM Mar 2026 | -$31.68M USD | +27.7% | — | 39.8% | |
| LTM Mar 2026 | -$45.97M USD | -0.0% | — | 77.8% | |
| LTM Mar 2026 | -$62.35M USD | +22.0% | — | 53.0% | |
| LTM Mar 2026 | -$70.61M USD | -31.5% | — | 843.9% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | -$89.21M USD | -28.4% | — | 864.8% |
| LTM Mar 2026 | -$100.08M USD | +56.8% | — | 258.7% | |
| LTM Mar 2026 | -$160.41M USD | +32.7% | — | — | |
| LTM Mar 2026 | -$171.58M USD | -48.1% | — | — | |
| LTM Mar 2026 | -CA$205.34M CAD | +57.2% | — | 65.7% | |
| Peer median (excluding ACH) | — | +11.0% | — | 71.8% | |
Competitors are the stored peer set for ACH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 9.79B | 9.96B | 10.33B | 10.7B | 2.76B |
| Cost of Revenue | 8.27B | 8.13B | 8.21B | 8.48B | 1.56B |
| Gross Profit | 1.51B | 1.83B | 2.13B | 2.22B | 1.2B |
| Gross Margin | 15.5% | 18.3% | 20.6% | 20.7% | 43.5% |
| Research & Development | 12.1M | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 1.08B | 1.55B | 1.81B | 1.91B | 1.05B |
| Operating Expenses | 1.14B | 1.68B | 2.02B | 2.43B | 1.05B |
| Depreciation & Amortization | 90.62M | 228.67M | 287.38M | 264.78M | 214.52M |
| EBITDA | 415.47M | 368.45M | 390.57M | 51.22M | 364.68M |
| EBITDA Margin | 4.2% | 3.7% | 3.8% | 0.5% | 13.2% |
| Operating Income | 368.47M | 142.91M | 104.51M | (207.77M) | 150.16M |
| Operating Margin | 3.8% | 1.4% | 1.0% | -1.9% | 5.4% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 48.09M | 128.89M | 157.92M | 143.8M | 129.2M |
| Other Income / Expenses | (91.72M) | (132.02M) | (159.23M) | (149.59M) | (252.11M) |
| Income Before Tax | 276.75M | 10.89M | (54.73M) | (357.36M) | (101.95M) |
| Pre-Tax Margin | 2.8% | 0.1% | -0.5% | -3.3% | -3.7% |
| Income Tax Expense | 55.17M | (11.5M) | (13.43M) | 5.33M | 729K |
| Net Income | 221.59M | 22.39M | (41.3M) | (362.69M) | (1.1B) |
| Net Margin | 2.3% | 0.2% | -0.4% | -3.4% | -39.8% |
| EPS (Basic) | 3.05 | 0.30 | (0.54) | (4.73) | (14.31) |
| EPS (Diluted) | 2.94 | 0.29 | (0.54) | (4.73) | (14.31) |
| Weighted Avg Shares | 72.74M | 74.5M | 75.79M | 76.74M | 76.9M |
| Weighted Avg Shares (Diluted) | 75.49M | 76.22M | 75.79M | 76.74M | 76.9M |
Accendra Health, Inc.
NYSE:ACH
Intrinsic Alpha fair value
Locked
Current Price
$0.71
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.